Sintilimab and Cardiovascular Toxicity —Reply

In Reply We thank Dr Peng and colleagues for their interest in the ORIENT-16 study and acknowledge their concerns about immune-related cardiotoxicities. All adverse events and their associations with treatment were carefully evaluated and reported per protocol. In Table 2 of the ORIENT-16 article, only common treatment-related adverse events (incidence of 15% or more, related to any drug) and immune-related adverse events (incidence of 2% or more) were listed in Table 2 of our article. Herein, we provide information about cardiotoxicity. Complete statistical tables are available upon request.
Source: JAMA - Journal of the American Medical Association - Category: General Medicine Source Type: research